Investor Relations | CHUGAI PHARMACEUTICAL CO., LTD.

Home > Investor Relations

1Q Results - Fiscal Year 2018(Jan-Mar 2018)

Apr 24, 2018 (16:30 JST)

Apr 17: Events & Presentations has been updated with the Time of the Financial Results
Apr 13: Webcast of Information Meeting on TECENTRIQ^®
Apr 12: Information Meeting on TECENTRIQ®
Apr 02: Updated Directors & Officers
Mar 29: Events & Presentations has been updated with the date of the Financial Results

More

Apr 20

Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan

[

PDF 115KB]

Apr 18

Launch of the Anti-Cancer Agent / a Humanized Anti-PD-L1 Monoclonal Antibody “TECENTRIQ^®”

[

PDF 93KB]

Apr 17

Chugai’s HEMLIBRA® Receives Breakthrough Therapy Designation
from U.S. FDA for Hemophilia A without Factor VIII Inhibitors -The Sixth Designation for Chugai Originated Drug-

[

PDF 198KB]

Apr 11

Waiver of Claims in Patent Infringement Lawsuit

[

PDF 18KB]

Mar 28

Favorable Ruling in Patent Infringement Lawsuit Relating to Emicizumab

[

PDF 17KB]

More

Management Policy

TSE Code:4519

Share Graph

Annual Report 2017 (Integrated Edition Including CSR Report)
[ 6.1MB]

Supplementary Materials

Chugai Pharmaceutical Co., Ltd. takes great care over the information presented on this website, but it does not guarantee its accuracy, completeness, usefulness, etc. Furthermore, Chugai Pharmaceutical Co., Ltd. will not be responsible for any damages resulting from the use of this website or the information presented on this website. For further details, please read the following "Terms and Conditions of Website Use."

Copyright © Chugai Pharmaceutical Co., Ltd. All rights reserved.